[{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Exystat","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Exystat","highestDevelopmentStatusID":"10","companyTruncated":"Biocodex \/ Exystat"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ PANTHERx Rare Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ PANTHERx Rare Pharmacy"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Nephrology","graph2":"Phase I","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Phase I","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"MRM Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2025","type":"Series B Financing","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Biocodex","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Biocodex","highestDevelopmentStatusID":"9","companyTruncated":"Biocodex \/ Biocodex"},{"orgOrder":0,"company":"Biocodex","sponsor":"Hilma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Biocodex \/ Biocodex","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ Biocodex"}]

Find Clinical Drug Pipeline Developments & Deals by Biocodex

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The net proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Undisclosed

                          September 04, 2025

                          Lead Product(s) : MH002

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : MRM Health

                          Deal Size : $64.0 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Diacomit (stiripentol) a GABA-A receptor inhibitor oral suspension, a new formulation is being investigated to aid in the treatment of dravet syndrome in young children.

                          Product Name : Diacomit

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 14, 2024

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Stiripentol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperoxaluria, Primary.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 18, 2024

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase III

                          Sponsor : Exystat

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Amoxicillin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Erythema Chronicum Migrans.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 11, 2024

                          Lead Product(s) : Amoxicillin Trihydrate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Stiripentol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 21, 2023

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : The acquisition is a key part of the Group’s international growth strategy and will enable Biocodex to consolidate its presence in the digestive health and women’s health segments of the US market.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 17, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Recipient : Hilma

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          07

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : DIACOMIT (stiripentol) is an effective treatment for seizures that are often resistant to other antiepileptic drugs. In two clinical studies, DIACOMIT reduced generalized clonic or tonic-clonic seizures by a median of 84% compared with 5.8% on placebo af...

                          Product Name : Diacomit

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 21, 2022

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : DIACOMIT (stiripentol), is a molecular entity approved by the FDA for the adjunctive treatment of seizures associated with Dravet syndrome in 2 years of age and older taking clobazam. An orally administered, DIACOMIT is given as either a capsule or powde...

                          Product Name : Diacomit

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          June 27, 2022

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : PANTHERx Rare Pharmacy

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Stiripentol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsies, Partial.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 15, 2022

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Stiripentol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 07, 2019

                          Lead Product(s) : Stiripentol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank